Beacon Investment Advisory Services Inc. Sells 64,807 Shares of Kenvue Inc. $KVUE

Beacon Investment Advisory Services Inc. decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 88.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 8,836 shares of the company’s stock after selling 64,807 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Kenvue were worth $169,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Elyxium Wealth LLC acquired a new position in shares of Kenvue in the 4th quarter valued at approximately $26,000. Johnson Financial Group Inc. bought a new stake in shares of Kenvue during the 2nd quarter worth approximately $26,000. MV Capital Management Inc. acquired a new stake in shares of Kenvue during the 4th quarter worth approximately $28,000. CoreCap Advisors LLC boosted its position in shares of Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 591 shares in the last quarter. Finally, Reflection Asset Management acquired a new stake in shares of Kenvue during the 4th quarter worth approximately $32,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Barclays lifted their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Finally, UBS Group lowered their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.27.

Kenvue Trading Down 3.4%

KVUE opened at $17.77 on Thursday. The company’s 50 day moving average is $19.13 and its 200-day moving average is $18.25. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $20.13. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The company has a market cap of $34.12 billion, a P/E ratio of 20.42, a PEG ratio of 1.64 and a beta of 0.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). The company had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted $0.29 earnings per share. Equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th were given a $0.21 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a yield of 4.7%. The ex-dividend date was Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is 96.55%.

Kenvue Profile

Kenvue Inc is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson’s and Band-Aid in baby care and essential health.